Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs

Research output: Contribution to journalJournal articleResearchpeer-review

  • Angel Tan
  • Spomenka Simovic
  • Andrew K Davey
  • Rades, Thomas
  • Clive A Prestidge
A silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules composed of medium-chain triglycerides, lecithin and silica nanoparticles; with an internal porous matrix structure, were shown to offer several physicochemical and biopharmaceutical advantages in comparison with unmodified drug, lipid emulsion, dry emulsion and the commercial product, Celebrex. DSC and XRD analyses confirmed non-crystalline CEL in SLH microcapsules and verified medium term physical stability. Dissolution under sink conditions revealed a 2- to 5-fold increase in dissolution efficiencies (%DE) and significantly reduced t(50%) (> or =50-fold) for CEL formulated as SLH microcapsules. Orally dosed in vivo studies in rats demonstrated superior pharmacokinetics for SLH microcapsules. Specifically, the fasted-state bioavailability (F) was statistically higher (p
Original languageEnglish
JournalJournal of controlled release : official journal of the Controlled Release Society
Issue number1
Pages (from-to)62-70
Number of pages9
Publication statusPublished - 2009
Externally publishedYes

ID: 40353307